Drug Type Antibody drug conjugate (ADC) |
Synonyms SHR A1912, SHR-A1912, SHRA1912 |
Target |
Action inhibitors |
Mechanism CD79B inhibitors(B-cell antigen receptor complex-associated protein beta chain inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse Large B-Cell Lymphoma | Phase 3 | China | 24 Apr 2025 | |
Diffuse large B-cell lymphoma recurrent | Phase 3 | China | 24 Apr 2025 |
Phase 1 | 49 | eqkjobkddr(nchckmpnos) = sxxfjsdlat uekoeduots (vtnnbtwjog, 39.8 - 71.5) | Positive | 24 May 2024 | |||
eqkjobkddr(nchckmpnos) = pelecxrpgc uekoeduots (vtnnbtwjog, 39.8 - 71.5) |